Status:

COMPLETED

A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Conditions:

Secondary Hyperparathyroidism

End Stage Renal Disease

Eligibility:

All Genders

18+ years

Brief Summary

The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of selective Vitamin D Receptor Activator's as it is prescribed in the normal cli...

Detailed Description

The scientific purpose of this study is to obtain data on the use of sVDRA(Selective Vitamin D Receptor Activator) in real-life clinical practice. This study will allow us to observe drug effectivenes...

Eligibility Criteria

Inclusion

  • Patients with secondary hyperparathyroidism in the presence of chronic kidney disease stage 5 and receiving hemodialysis who is treated with sVDRA's (Selective Vitamin D Receptor Activator) injection
  • iPTH (intact parathyroid hormone) \>300pg/ml, corrected serum Ca (Calcium) \< 10.2 mg/dl, serum P (Phosphorus) \< 6 mg/dl
  • Male and female (not pregnant or not planning to be pregnant in the next 12 months) patients equal to or older than 18 years of age
  • Signed Informed consent by subject
  • Hypertensive and Diabetic subjects must be on an optimal and steady medication regimen for more than 30 days

Exclusion

  • Subject has known hypersensitivity and/or toxicity to vitamin D metabolites and/or other product ingredients
  • Subject has participated in a clinical study within the last month
  • If sVDRA's (Selective Vitamin D Receptor Activator) are contraindicated according to the SmPC (Summary of Product Characteristics)

Key Trial Info

Start Date :

July 1 2011

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2014

Estimated Enrollment :

511 Patients enrolled

Trial Details

Trial ID

NCT01149291

Start Date

July 1 2011

End Date

December 1 2014

Last Update

January 12 2015

Active Locations (22)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (22 locations)

1

Site Reference ID/Investigator# 37822

Antalya, Turkey (Türkiye), 07059

2

Site Reference ID/Investigator# 68286

Antalya, Turkey (Türkiye), 7130

3

Site Reference ID/Investigator# 40677

Antalya, Turkey (Türkiye)

4

Site Reference ID/Investigator# 85153

Istanbul, Turkey (Türkiye), 34180

A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism | DecenTrialz